Search Results

The National Directory of Mental Health Treatment Facilities - 2020 is a listing of federal, state, and local government facilities and private facilities that provide mental health treatment services. It includes treatment facilities that responded to the 2019 National Mental Health Services Survey (N-MHSS). The information about each facility that...

The National Directory of Mental Health Treatment Facilities - 2019 is a listing of federal, state, and local government facilities and private facilities that provide mental health treatment services. It includes treatment facilities that responded to the 2018 National Mental Health Services Survey (N-MHSS). The information about each facility that...

This short report uses data from the Drug Abuse Warning Network (DAWN) to examine the emergency department (ED) visits for children aged 1 -5 that involved opioid pain relievers. Hydrocodone (Vicodin, Lortab), oxycodone (OxyContin, Percocet), and codeine are examples of opioid pain relievers; buprenorphine (Suboxone), is an opioid that is...

The purpose of this report is to describe the differences between the DSM-IV and DSM-5 diagnostic criteria that could affect national estimates of childhood serious emotional disturbance (SED). The report also provides a description of DSM-5 updates
that have been made (or are being made) to existing diagnostic instruments and...

With growing recognition of the impact of trauma exposure on behavioral health outcomes, the Substance Abuse and Mental Health Services Administration (SAMHSA) is interested in evaluating associations between potentially traumatic events (PTEs) with mental health and substance use issues. The 2008-2012 National Survey on Drug Use and Health (NSDUH) Mental...

2014 Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables. The URS is a state, national, and territories reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization...

This report presents estimates of the numbers and percentages of adults aged 18 or older with past 12-month mental disorders, as assessed by the Mental Health Surveillance Study (MHSS) clinical study, a subset to the 2008 to 2012 National Survey of Drug Use and Health (NSDUH). The assessment included a...

This short report uses data on drug-related emergency department (ED) visits from the Drug Abuse Warning Network to examine the trends in ED visits involving methamphetamine from 2007 to 2011. In addition to the trends for total methamphetamine-related visits, it also shows trends by gender and by age group; the...

Excel file with national estimates, rates, relative standard errors, trends and confidence intervals for all drug-related emergency department (ED) visits, covering 2004-2011. File includes all drug-related ED visits that are reportable to DAWN without regard for the reason for the visit or the specific drugs involved. It includes visits involving...

This Drug Abuse Warning Network (DAWN) short report shows the estimated number of emergency room visits involving attention deficit/hyperactivity disorder stimulant medications between 2005 and 2010. The report shows visits for nonmedical use, adverse reactions, visits involving other pharmaceuticals, illicit drugs or alcohol.

This Drug Abuse Warning Network (DAWN) report shows emergency room visits in 2010 involving synthetic cannabinoid products commonly called \"Spice\" or \"K2\". These drugs are also known as synthetic marijuana,

This publication provides behavioral health statistics at the national and state levels from multiple data sources, including the National Survey on Drug Use and Health, the National Health Interview Survey, the Medical Expenditures Panel Survey, the National Association of State Mental Health Program Directors, as well as peer-reviewed journal articles.

This Drug Abuse Warning Network (DAWN) short report discusses emergency department visits by children who consumed psychothapeutic drugs. It looks at the reasons for the visits (adverse reactions and accidental ingestion) for ages 0-5 and 6-11.